When evaluating parameter uncertainty is not enough: the case of dasatinib and nilotinib for imatinib-resistant chronic myeloid leukemia
- PMID: 22152174
- DOI: 10.1016/j.jval.2011.10.001
When evaluating parameter uncertainty is not enough: the case of dasatinib and nilotinib for imatinib-resistant chronic myeloid leukemia
Comment on
-
Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia.Value Health. 2011 Dec;14(8):1057-67. doi: 10.1016/j.jval.2011.07.006. Epub 2011 Oct 12. Value Health. 2011. PMID: 22152175
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
